Association between cause of kidney failure and fracture incidence in a national US dialysis population cohort study.
dialysis
end-stage kidney disease
fracture
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
23
03
2022
entrez:
16
11
2022
pubmed:
17
11
2022
medline:
17
11
2022
Statut:
epublish
Résumé
Whether fracture rates, overall and by fracture site, vary by cause of kidney failure in patients receiving dialysis is unknown. Using the US Renal Data System, we compared fracture rates across seven causes of kidney failure in patients who started dialysis between 1997 and 2014. We computed unadjusted and multivariable adjusted proportional sub-distribution hazard models, with fracture events (overall, and by site) as the outcome and immunoglobulin A nephropathy as the reference group. Kidney transplantation and death were competing events. Among 491 496 individuals, with a median follow-up of 2.0 (25%, 75% range 0.9-3.9) years, 62 954 (12.8%) experienced at least one fracture. Patients with diabetic nephropathy, vasculitis or autosomal polycystic kidney disease (ADPKD) had the highest (50, 46 and 40 per 1000 person-years, respectively), and patient with lupus nephritis had the lowest (20 per 1000 person-years) fracture rates. After multivariable adjustment, diabetic nephropathy [hazard ratio (HR) 1.43, 95% confidence interval 1.33-1.53], ADPKD (HR 1.37, 1.26-1.48), vasculitis (HR 1.22, 1.09-1.34), membranous nephropathy (HR 1.16, 1.02-1.30) and focal segmental glomerulosclerosis (FSGS) (HR 1.13, 1.02-1.24) were associated with a significantly higher, and lupus nephritis with a significantly lower (HR 0.85, 0.71-0.98) fracture hazard. The hazards for upper extremity and lower leg fractures were significantly higher in diabetic nephropathy, ADPKD, FSGS and membranous nephropathy, while the hazard for vertebral fracture was significantly higher in vasculitis. Our findings were limited by the lack of data on medication use and whether fractures were traumatic or non-traumatic, among other factors. Fracture risk, overall and by fracture site, varies by cause of end-stage kidney disease. Future work to determine underlying pathogenic mechanisms contributing to differential risks might inform more tailored treatment strategies. Our study was limited by lack of data regarding numerous potential confounders or mediators including medications and measures or bone biomarkers.
Sections du résumé
Background
UNASSIGNED
Whether fracture rates, overall and by fracture site, vary by cause of kidney failure in patients receiving dialysis is unknown.
Methods
UNASSIGNED
Using the US Renal Data System, we compared fracture rates across seven causes of kidney failure in patients who started dialysis between 1997 and 2014. We computed unadjusted and multivariable adjusted proportional sub-distribution hazard models, with fracture events (overall, and by site) as the outcome and immunoglobulin A nephropathy as the reference group. Kidney transplantation and death were competing events.
Results
UNASSIGNED
Among 491 496 individuals, with a median follow-up of 2.0 (25%, 75% range 0.9-3.9) years, 62 954 (12.8%) experienced at least one fracture. Patients with diabetic nephropathy, vasculitis or autosomal polycystic kidney disease (ADPKD) had the highest (50, 46 and 40 per 1000 person-years, respectively), and patient with lupus nephritis had the lowest (20 per 1000 person-years) fracture rates. After multivariable adjustment, diabetic nephropathy [hazard ratio (HR) 1.43, 95% confidence interval 1.33-1.53], ADPKD (HR 1.37, 1.26-1.48), vasculitis (HR 1.22, 1.09-1.34), membranous nephropathy (HR 1.16, 1.02-1.30) and focal segmental glomerulosclerosis (FSGS) (HR 1.13, 1.02-1.24) were associated with a significantly higher, and lupus nephritis with a significantly lower (HR 0.85, 0.71-0.98) fracture hazard. The hazards for upper extremity and lower leg fractures were significantly higher in diabetic nephropathy, ADPKD, FSGS and membranous nephropathy, while the hazard for vertebral fracture was significantly higher in vasculitis. Our findings were limited by the lack of data on medication use and whether fractures were traumatic or non-traumatic, among other factors.
Conclusions
UNASSIGNED
Fracture risk, overall and by fracture site, varies by cause of end-stage kidney disease. Future work to determine underlying pathogenic mechanisms contributing to differential risks might inform more tailored treatment strategies. Our study was limited by lack of data regarding numerous potential confounders or mediators including medications and measures or bone biomarkers.
Identifiants
pubmed: 36381373
doi: 10.1093/ckj/sfac193
pii: sfac193
pmc: PMC9664571
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2245-2257Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.
Références
Rheumatology (Oxford). 2000 Dec;39(12):1383-9
pubmed: 11136882
Arthritis Rheumatol. 2019 Jul;71(7):1141-1146
pubmed: 30714690
Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1413-21
pubmed: 27269611
Am J Kidney Dis. 2020 Mar;75(3):351-360
pubmed: 31606233
J Bone Miner Res. 1989 Jun;4(3):283-91
pubmed: 2763869
Am J Epidemiol. 2009 Jul 15;170(2):244-56
pubmed: 19494242
Curr Opin Nephrol Hypertens. 2010 Jul;19(4):343-8
pubmed: 20414109
Kidney Int. 2006 Oct;70(7):1358-66
pubmed: 16929251
Osteoporos Int. 2014 Jan;25(1):159-65
pubmed: 23835863
J Pathol. 2002 Oct;198(2):220-7
pubmed: 12237882
Am J Kidney Dis. 2016 Feb;67(2):218-226
pubmed: 26250781
Kidney Int Rep. 2017 Jan 10;2(3):481-485
pubmed: 29142975
Biomed Res. 2018;39(3):131-139
pubmed: 29899188
Kidney Int. 2021 Apr;99(4):977-985
pubmed: 32926884
Cytokine Growth Factor Rev. 2004 Feb;15(1):49-60
pubmed: 14746813
Kidney Int. 2014 Oct;86(4):810-8
pubmed: 24429401
J Bone Miner Res. 2009 Mar;24(3):503-13
pubmed: 19016583
Endocrinology. 2003 May;144(5):1761-9
pubmed: 12697681
Am J Kidney Dis. 2000 Dec;36(6):1115-21
pubmed: 11096034
Curr Osteoporos Rep. 2015 Apr;13(2):106-15
pubmed: 25648962
J Bone Miner Res. 2016 Oct;31(10):1803-1809
pubmed: 27145189
Clin J Am Soc Nephrol. 2014 Jul;9(7):1328-35
pubmed: 24509298
Pediatrics. 1985 Aug;76(2):280-5
pubmed: 3839579
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Clin Endocrinol Metab. 1998 Jun;83(6):1860-2
pubmed: 9626109
Kidney Int. 2008 Sep;74(6):721-31
pubmed: 18563052
Bone. 2007 Jul;41(1):19-24
pubmed: 17490921
Pediatr Nephrol. 1995 Jun;9(3):278-81
pubmed: 7632510
Clin J Am Soc Nephrol. 2010 Nov;5(11):2046-52
pubmed: 20688886
Osteoporos Int. 2013 Sep;24(9):2493-8
pubmed: 23572142